TOUJEO SOLOSTAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOUJEO SOLOSTAR (TOUJEO SOLOSTAR).
Insulin glargine is a long-acting human insulin analog that binds to the insulin receptor, activating cellular glucose uptake and inhibiting hepatic glucose production.
| Metabolism | Metabolized by degradation into metabolites M1 and M2, partially via the insulin-degrading enzyme. No significant cytochrome P450 involvement. |
| Excretion | Renal excretion of degradation products; minimal intact insulin in urine. Fecal elimination is negligible. |
| Half-life | Terminal half-life: 19 hours (range 14–24 hours) after subcutaneous administration due to slow absorption from injection site. |
| Protein binding | 99.7% bound to albumin and beta-globulins. |
| Volume of Distribution | 0.08 L/kg (low, indicating limited extravascular distribution). |
| Bioavailability | Subcutaneous: Approximately 100% after injection. |
| Onset of Action | Subcutaneous: 2–4 hours. |
| Duration of Action | Subcutaneous: 24–36 hours, up to 40 hours. Provides steady basal insulin levels with once-daily dosing. |
Subcutaneous injection once daily at the same time each day. Starting dose in insulin-naïve patients: 0.2 units/kg or 10 units once daily, titrated to achieve glycemic targets. Maximum single dose: 80 units per injection.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment based on GFR; however, reduced renal function increases risk of hypoglycemia. Monitor blood glucose closely and adjust dose as needed. Use with caution in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No specific adjustment based on Child-Pugh score; hepatic impairment may increase risk of hypoglycemia. Monitor blood glucose closely and titrate dose carefully. |
| Pediatric use | Not approved for use in pediatric patients (age <18 years). Safety and effectiveness not established. |
| Geriatric use | Initiate at lower doses (e.g., 0.1–0.2 units/kg) due to increased risk of hypoglycemia. Titrate slowly and monitor glucose levels frequently. Consider reduced starting dose in frail elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOUJEO SOLOSTAR (TOUJEO SOLOSTAR).
| Breastfeeding | Insulin glargine is excreted in human breast milk in negligible amounts. No data on M/P ratio. Considered compatible with breastfeeding, but monitor infant for signs of hypoglycemia. |
| Teratogenic Risk | Insulin glargine does not cross the placenta in significant amounts. Data from clinical trials and postmarketing studies do not indicate an increased risk of major congenital malformations with use during pregnancy. However, poor glycemic control is associated with fetal anomalies, macrosomia, and neonatal hypoglycemia. First trimester: No evidence of teratogenicity. Second/third trimester: Risk of fetal macrosomia and neonatal hypoglycemia if maternal glucose control is suboptimal. Peripartum: Increased risk of neonatal hypoglycemia if maternal glucose control is inadequate. |
■ FDA Black Box Warning
Not recommended during episodes of hypoglycemia or in patients with hypersensitivity to insulin glargine or any excipients. Not recommended for treatment of diabetic ketoacidosis. Do not dilute or mix with other insulins.
| Common Effects | Hypoglycemia low blood glucose level Peripheral edema Lipodystrophy skin thickening or pits at the injection site Allergic reaction Injection site reactions pain swelling redness Itching Rash Weight gain |
| Serious Effects |
["Hypersensitivity to insulin glargine or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia: Most common adverse reaction, may be severe and life-threatening","Hypokalemia: Can cause hypokalemia, potentially leading to cardiac arrhythmias","Accidental mix-ups: Use only the Toujeo SoloStar pen; do not interchange with other insulin glargine products","Fluid retention and heart failure: Use cautiously with thiazolidinediones (TZDs)","Immune hypersensitivity: Severe, life-threatening allergic reactions possible","Medication errors: Never share pens or needles"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c regularly. For fetal monitoring: monthly ultrasound for growth assessment; nonstress test or biophysical profile as clinically indicated, especially in third trimester if insulin resistance increases. Monitor for neonatal hypoglycemia after delivery. |
| Fertility Effects | No evidence of impaired fertility in animal studies. In humans, uncontrolled diabetes can impair fertility; improved glycemic control with insulin may improve fertility outcomes. |